The pace of change to value-based payments has been happening quickly, but the real test is whether or not these payments produce higher quality and more affordable care, said Suzanne Delbanco, PhD, MPH, executive director of Catalyst for Payment Reform.
The pace of change to value-based payments has been happening quickly, but the real test is whether or not these payments produce higher quality and more affordable care, said Suzanne Delbanco, PhD, MPH, executive director of Catalyst for Payment Reform.
Transcript
Has the move to value-based payments been happening as quickly as you expected?
When we got started in 2010, there was so little value-based payment; It was maybe between 1% and 3% of payments, and in the last 7-and-a-half, 8 years, we’re at 50% now. So, I think that’s a pretty remarkable and fast change to how were paying healthcare providers. The big question is, how well are these payments working to produce the higher quality and more affordable care that we hoped they would?
What have been the outcomes seen so far in the move to value-based payments?
As a whole, I would say the outcomes of these value-based payment movement and the growth of payment reform are mixed. So far, we’ve seen some really great examples of improvements in certain quality measures and even more efficient use of resources. But, we’ve also seen examples of where there were really disappointing results, and we can’t even specify the positive or negative results by payment method. Even within a program and bundled payment, you might see some quality measures getting better, and some not. In an ACO environment supported by shared savings, you might see that length of stay in the hospital was reduced, but there was no impact on adherence to guideline for diabetes care. So far, were seeing real mixed results, even by payment methods.
How Access to SMA Treatment Varies Globally and by Insurance Type
March 18th 2025Posters presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference show that therapeutic advances in treating spinal muscular atrophy (SMA) are not uniformly making it into the hands of patients who could benefit.
Read More
Bustling Gene Therapy Pipeline for Neuromuscular Diseases Brings Thorny Questions to the Clinic
March 18th 2025The rapid development of gene therapy options for treating neuromuscular diseases has created new therapeutic options but also logistical hurdles and a need for complex discussions between clinicians and families.
Read More
Solving the Transition Conundrum as More Children With Muscular Dystrophy Live to Adulthood
March 17th 2025Learning from examples like congenital heart disease and cystic fibrosis can help health systems and clinicians prepare to care for an influx of patients with neuromuscular diseases as they reach adulthood thanks to transformative therapy advances.
Read More
For Neuromuscular Disease Community, an Era of Opportunities and Threats
March 17th 2025Robert Califf, MD, former commissioner of the FDA, delivered a keynote address at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference that highlighted the enormous opportunities for progress in neuromuscular disease care amid a changing policy environment.
Read More